

Cell-potent and Selective Inhibitors for Nicotinamide N-methyltransferase

A rigorous physics-based software model improves prediction of multiple protein-protein interactions, outperforming previous methods in unbound docking cases.

NCS: Researchers at Purdue University have synthesized a series of cell-potent and selective inhibitors of nicotinamide N-methyltransferase (NNMT) that can be used to treat cancer, metabolic and neurodegenerative diseases. NNMT plays an important role in regulating both epigenetics and metabolism by methylating nicotinamide. Elevated levels of NNMT have been associated with diseases like cancer, liver disease, diabetes, and obesity. The most potent compound (IC₅₀ =3.4 nM) synthesized by the Purdue researchers had an IC₅₀ value of 100 nanomolar for inhibiting N-methylated Nicotinamide in cells, over 1000-fold selectivity for NNMT compared to related methyltransferases. Moreover, cell-potent NNMT inhibitors exhibit a favorable pharmacokinetics profile.

Related Publications: Chen D, Li L, Diaz K, Iyamu ID, Yadav R, Noinaj N, Huang R. (2019) Novel propargyl-linked bisubstrate analogs as tight-binding Inhibitors for nicotinamide N-methyltransferase. *Journal of Medicinal Chemistry*. 62 (23), 10783-10797. PMID: 31724854; PMCID: PMC7296983. www.ncbi.nlm.nih.gov/pubmed/31724854

Iyamu ID, Vilseck JZ, Yadav R, Noinaj N, Huang R. (2022) Exploring unconventional SAM analogues to build cell-potent bisubstrate inhibitors for nicotinamide N-methyltransferase. *Angewandte Chemie International Edition*. <https://doi.org/10.1002/anie.202114813>

Advantages

- Selective
- Low concentration

Technology ID
2021-HUAN-69352

Category

Biotechnology & Life Sciences/Bioinformatics & Computational Biology
Artificial Intelligence & Machine Learning/AI Model Optimization & Acceleration Tools
Pharmaceuticals/Other
Pharmaceuticals/Research Tools & Assays

Authors

Rong Huang
Iredia Iyamu

Further information

Joe Kasper
JKKasper@prf.org

Nathan Smith
nesmith@prf.org

View online



Applications

-Metabolic disorders

-Cancers

-Neurodegenerative diseases

TRL: 2

Intellectual Property:

Provisional-Patent, 2021-11-22, United States | PCT-Patent, 2022-11-21, WO
| NATL-Patent, 2022-11-21, Europe | NATL-Patent, 2024-05-22, United States

Keywords: nicotinamide N-methyltransferase inhibitors, NNMT inhibitors, cell-potent inhibitors, selective inhibitors, cancer treatment, metabolic disease treatment, neurodegenerative disease treatment, epigenetics, metabolism, small molecule drugs